MRVI's Aroon Indicator triggered a bullish signal on October 13, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 172 similar instances where the Aroon Indicator showed a similar pattern. In 152 of the 172 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 88%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on MRVI as a result. In 77 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for MRVI just turned positive on October 26, 2026. Looking at past instances where MRVI's MACD turned positive, the stock continued to rise in 36 of 47 cases over the following month. The odds of a continued upward trend are 77%.
MRVI moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MRVI crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +12.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRVI advanced for three days, in 204 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The 10-day RSI Indicator for MRVI moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 24 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRVI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
MRVI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.687) is normal, around the industry mean (3.154). P/E Ratio (-14.736) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (4.785) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. MRVI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRVI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
TWST saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 77 similar instances where the indicator turned positive. In 69 of the 77 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
The Moving Average Convergence Divergence (MACD) for TWST just turned positive on October 28, 2026. Looking at past instances where TWST's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
Following a +19.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 235 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 181 of 228 cases where TWST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
The 10-day RSI Indicator for TWST moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 39 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
TWST moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TWST crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TWST broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.725) is normal, around the industry mean (3.154). TWST has a moderately low P/E Ratio (-68.511) as compared to the industry average of (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TWST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
MRVI | TWST | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 21 | 10 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 16 Undervalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 71 | |
SMR RATING 1..100 | 97 | 97 | |
PRICE GROWTH RATING 1..100 | 34 | 34 | |
P/E GROWTH RATING 1..100 | 59 | 95 | |
SEASONALITY SCORE 1..100 | n/a | 44 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TWST's Valuation (4) in the Biotechnology industry is in the same range as MRVI (16) in the null industry. This means that TWST’s stock grew similarly to MRVI’s over the last 12 months.
TWST's Profit vs Risk Rating (71) in the Biotechnology industry is in the same range as MRVI (100) in the null industry. This means that TWST’s stock grew similarly to MRVI’s over the last 12 months.
TWST's SMR Rating (97) in the Biotechnology industry is in the same range as MRVI (97) in the null industry. This means that TWST’s stock grew similarly to MRVI’s over the last 12 months.
TWST's Price Growth Rating (34) in the Biotechnology industry is in the same range as MRVI (34) in the null industry. This means that TWST’s stock grew similarly to MRVI’s over the last 12 months.
MRVI's P/E Growth Rating (59) in the null industry is somewhat better than the same rating for TWST (95) in the Biotechnology industry. This means that MRVI’s stock grew somewhat faster than TWST’s over the last 12 months.
| MRVI | TWST | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 80% | 2 days ago 87% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 77% | 2 days ago 87% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 84% |
| Advances ODDS (%) | 4 days ago 79% | 4 days ago 80% |
| Declines ODDS (%) | 2 days ago 83% | 16 days ago 86% |
| BollingerBands ODDS (%) | 2 days ago 88% | 2 days ago 80% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 79% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRVI’s FA Score shows that 1 FA rating(s) are green while TWST’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRVI’s TA Score shows that 6 TA indicator(s) are bullish while TWST’s TA Score has 4 bullish TA indicator(s).
MRVI (@Biotechnology) experienced а +6.69% price change this week, while TWST (@Biotechnology) price change was +9.19% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was -14.01%, and the average quarterly price growth was -15.33%.
MRVI is expected to report earnings on Nov 04, 2026.
TWST is expected to report earnings on Nov 12, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, MRVI has been loosely correlated with MRNA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if MRVI jumps, then MRNA could also see price increases.
| Ticker / NAME | Correlation To MRVI | 1D Price Change % | ||
|---|---|---|---|---|
| MRVI | 100% | -7.68% | ||
| MRNA - MRVI | 46% Loosely correlated | -0.47% | ||
| TWST - MRVI | 43% Loosely correlated | -11.92% | ||
| BNTX - MRVI | 41% Loosely correlated | -1.08% | ||
| RXRX - MRVI | 40% Loosely correlated | -4.95% | ||
| ARCT - MRVI | 39% Loosely correlated | -9.22% | ||
More | ||||